Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Selecta Biosciences Appoints CMO

This article was originally published in Scrip

Executive Summary

Selecta Biosciences Inc., which is developing a novel class of targeted antigen-specific immune therapies using Synthetic Vaccine Particles (SVP), has appointed Dr Earl Sands as chief medical officer. Prior to joining Selecta, Sands was most recently chief medical officer of Targacept.



Related Companies